205 related articles for article (PubMed ID: 37607037)
1. Role of Cardiac Biomarkers in Monitoring Cardiotoxicity in Chemotherapy Patients.
Battisha A; Sawalha K; Obeidat Y; Patel B
Crit Pathw Cardiol; 2023 Sep; 22(3):83-87. PubMed ID: 37607037
[TBL] [Abstract][Full Text] [Related]
2. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
[TBL] [Abstract][Full Text] [Related]
3. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM
Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087
[TBL] [Abstract][Full Text] [Related]
4. The Role of Biomarkers in Cardio-Oncology.
Ananthan K; Lyon AR
J Cardiovasc Transl Res; 2020 Jun; 13(3):431-450. PubMed ID: 32642841
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond.
Attanasio U; Di Sarro E; Tricarico L; Di Lisi D; Armentaro G; Miceli S; Fioretti F; Deidda M; Correale M; Novo G; Sciacqua A; Nodari S; Cadeddu C; Tocchetti CG; Palazzuoli A; Mercurio V
Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397436
[TBL] [Abstract][Full Text] [Related]
6. The Role of Biomarkers to Evaluate Cardiotoxicity.
Upshaw JN
Curr Treat Options Oncol; 2020 Aug; 21(10):79. PubMed ID: 32767198
[TBL] [Abstract][Full Text] [Related]
7. [MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)].
Saganelidze K; Kavtaradze N
Georgian Med News; 2018 May; (278):87-93. PubMed ID: 29905551
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues.
Bracun V; Aboumsallem JP; van der Meer P; de Boer RA
Curr Oncol Rep; 2020 Jun; 22(7):67. PubMed ID: 32514994
[TBL] [Abstract][Full Text] [Related]
9. Disparities in cardio-oncology: Implication of angiogenesis, inflammation, and chemotherapy.
Vera CD; López AR; Ewaneewane AS; Lewis K; Parmisano S; Mondejar-Parreño G; Upadhyaya C; Mullen M
Life Sci; 2023 Nov; 332():122106. PubMed ID: 37730108
[TBL] [Abstract][Full Text] [Related]
10. The role of cardiac biomarkers in cardio-oncology.
Riddell E; Lenihan D
Curr Probl Cancer; 2018 Jul; 42(4):375-385. PubMed ID: 30126650
[TBL] [Abstract][Full Text] [Related]
11. Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology.
Kostakou PM; Kouris NT; Kostopoulos VS; Damaskos DS; Olympios CD
Heart Fail Rev; 2019 Jan; 24(1):91-100. PubMed ID: 30073443
[TBL] [Abstract][Full Text] [Related]
12. Update on Incorporating Biomarkers with Imaging Findings for the Detection and Management of Cardiotoxicity.
Quatromoni N; Scherrer-Crosbie M
Curr Cardiol Rep; 2018 Jun; 20(8):67. PubMed ID: 29931487
[TBL] [Abstract][Full Text] [Related]
13. Left Ventricular Dysfunction and Chemotherapeutic Agents.
Clasen SC; Wald JW
Curr Cardiol Rep; 2018 Mar; 20(4):20. PubMed ID: 29520629
[TBL] [Abstract][Full Text] [Related]
14. Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity.
O'Hare M; Murphy K; Mookadam F; Sharma A; Lee H
Expert Rev Cardiovasc Ther; 2015 May; 13(5):519-27. PubMed ID: 25864865
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity due to Chemotherapy: the Role of Biomarkers.
Stevens PL; Lenihan DJ
Curr Cardiol Rep; 2015 Jul; 17(7):603. PubMed ID: 26026994
[TBL] [Abstract][Full Text] [Related]
16. Cancer Therapy-Related Cardiac Dysfunction: Unresolved Issues.
Marwick TH
Can J Cardiol; 2016 Jul; 32(7):842-6. PubMed ID: 27343742
[TBL] [Abstract][Full Text] [Related]
17. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis.
Michel L; Mincu RI; Mahabadi AA; Settelmeier S; Al-Rashid F; Rassaf T; Totzeck M
Eur J Heart Fail; 2020 Feb; 22(2):350-361. PubMed ID: 31721381
[TBL] [Abstract][Full Text] [Related]
18. Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer.
Lakhani HV; Pillai SS; Zehra M; Dao B; Tirona MT; Thompson E; Sodhi K
Sci Rep; 2021 Apr; 11(1):7954. PubMed ID: 33846495
[TBL] [Abstract][Full Text] [Related]
19. Identifying cancer patients at risk for cardiotoxicity.
Salvatici M; Sandri MT
Future Oncol; 2015; 11(14):2077-91. PubMed ID: 26198838
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors-Related Cardiotoxicity.
Konala VM; Adapa S; Aronow WS
Am J Ther; 2020; 27(6):e591-e598. PubMed ID: 31008763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]